证券代码：603139 证券简称：康惠制药 公告编号：2025-053 陕西康惠制药股份有限公司 关于2025年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所发布的上市公司分行业信息披露指引及《关于做好主板 上市公司 2025 年半年度报告披露工作的重要提醒》相关要求，现将公司 2025 年半年度主要经营数据披露如下： 单位：万元 项 目 营业收入 营业成本 毛利率（%） 营业收入比上 年增减（%） 营业成本比上 年增减（%） 毛利率比上 年增减(%) 妇科类 1,696.76 797.63 52.99 -18.36 -3.78 -7.12 呼吸感冒类 1,959.29 1,325.23 32.36 -16.12 -4.40 -8.29 皮肤科类 3,226.09 1,033.64 67.96 -14.07 -20.65 2.66 骨科类 1,547.02 912.91 40.99 11.01 49.94 -15.32 其他 3,262.43 1,673.08 48.72 84.7 ...

Core Viewpoint - Kanghui Pharmaceutical (603139) reported a decline in revenue and a significant net loss for the first half of 2025, indicating challenges in its operational performance and market conditions [1] Financial Performance - The company achieved an operating revenue of 248 million yuan, representing a year-on-year decrease of 6.83% [1] - The net profit attributable to shareholders was -40.20 million yuan, with a basic earnings per share of -0.4 yuan [1] Reasons for Performance Decline - The significant loss was primarily due to: 1. High depreciation and financing loan interest expenses at the subsidiary Shaanxi Youbang, coupled with unfavorable market supply and demand dynamics, leading to substantial losses in the first half of 2025 [1] 2. The subsidiary Chunsheng Pharmaceutical experienced a notable business decline due to adverse market conditions, resulting in considerable losses [1] 3. Increased costs and expenses at the parent company level [1]

Group 1 - The company reported a revenue of 248 million yuan for the first half of the year, representing a year-on-year decrease of 6.83% [1] - The net profit attributable to shareholders was a loss of 40.2 million yuan, compared to a loss of 8.7 million yuan in the same period last year [1] - The basic earnings per share were -0.4 yuan [1]

Core Viewpoint - Kanghui Pharmaceutical (603139.SH) reported a decline in revenue and an increase in net losses for the first half of 2025, indicating financial challenges for the company [1] Financial Performance - The company's operating revenue for the first half of 2025 was 248 million yuan, a year-on-year decrease of 6.83% [1] - The net loss attributable to shareholders of the listed company was 40.2036 million yuan, which represents a year-on-year increase of 362.01% [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 42.8271 million yuan, reflecting a year-on-year increase of 167.89% [1] - The basic loss per share was 0.4 yuan [1]

Core Points - The company, Shaanxi Kanghui Pharmaceutical Co., Ltd., has obtained a new drug production license valid until August 24, 2030, ensuring compliance and continuity in operations [1][2] - The new license was issued by the Shaanxi Provincial Drug Administration due to the expiration of the previous license, which is a routine regulatory process [1][2] Company Information - The new drug production license number is 陕 20160073, and the company is located in Xi'an, Shaanxi Province [1] - The legal representative and responsible person for quality is Wang Yanling, while the production manager is Guo Jiangang [1] Production Scope - The company is authorized to produce a variety of pharmaceutical forms including plasters, ointments, granules, hard capsules, tablets, tinctures, and more across multiple production sites in Xi'an [1]

Core Viewpoint - Kanghui Pharmaceutical announced the acquisition of a new drug production license from the Shaanxi Provincial Drug Administration, effective August 25, 2025 [2] Company Summary - Kanghui Pharmaceutical received a renewed drug production license, indicating compliance with regulatory standards and potential for increased production capacity [2]

Group 1 - The core point of the article is that Kanghui Pharmaceutical has provided guarantees totaling approximately 112 million yuan for its subsidiaries, which represents 13.35% of the company's latest audited net assets [1] - As of the announcement date, the market capitalization of Kanghui Pharmaceutical is 2.4 billion yuan [1] - The revenue composition for Kanghui Pharmaceutical in 2024 is as follows: 49.58% from pharmaceutical manufacturing, 47.35% from pharmaceutical distribution, and 3.07% from other businesses [1] Group 2 - The company has provided a guarantee balance of 2.8 million yuan for its wholly-owned subsidiary [1] - The A-share market has seen a continuous trading volume exceeding 2 trillion yuan for eight consecutive days, indicating a robust trading environment [1] - Major industry players are actively recruiting for 25 positions, highlighting a demand for talent in the sector [1]

关于为控股子公司提供担保的公告 证券代码：603139 证券简称：康惠制药 公告编号：2025-051 陕西康惠制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | | | 被担保人名称 本次担保金额 | 480 | 四川春盛药业集团股份有限公司 万元 | | | --- | --- | --- | --- | --- | --- | | 担 | 保 对 | | | | | | 象 | | 实际为其提供的担保余额 | 2,880 | 万元 | | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | | 本次担保是否有反担保 | 是 | □否 | □不适用：_________ | 担保对象及基本情况 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股子公司对外担保总额（万元） | 11,442.84 | | 对外担保总额占上市公司最近一期经审计净资产的比例（%） | 13.35 ...

证券代码：603139 证券简称：康惠制药 公告编号：2025-052 陕西康惠制药股份有限公司 关于换发药品生产许可证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、《药品生产许可证》的主要信息 企业名称：陕西康惠制药股份有限公司 许可证编号：陕 20160073 社会信用代码：916100006984144239 分类码：AhzCz 注册地址：陕西省咸阳市秦都区高新技术产业开发区彩虹二路 法定代表人：王延岭 企业负责人：王延岭 质量负责人：郝红梅 质量授权人：郝红梅 陕西康惠制药股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日取得 陕西省药品监督管理局换发的《药品生产许可证》（许可证编号：陕 20160073）， 换发后的《药品生产许可证》有效期至 2030 年 8 月 24 日，具体情况如下： 生产地址和生产范围： 陕西省咸阳市秦都区高新技术产业开发区胭脂路 36 号：膏药，软膏剂，茶 剂，颗粒剂，硬胶囊剂，片剂，酒剂，合剂，搽剂，酊剂，洗剂； 陕西省咸阳市秦都区高新开发区高新路:搽剂,酊剂 ...

Group 1 - The company held its 18th meeting of the 5th Board of Directors on August 19, 2025, with all 9 directors present, confirming the legality and validity of the meeting [2][5] - The board approved the proposal to cancel the supervisory board and amend the Articles of Association, transferring the supervisory board's powers to the audit committee of the board [3][39] - The proposal to amend the Articles of Association requires approval at the company's second extraordinary general meeting in 2025 [4] Group 2 - The board also approved the revision of 23 governance rules to enhance the company's governance structure, which will also be submitted for approval at the upcoming extraordinary general meeting [6][39] - A new management system for the departure of directors and senior management was established and disclosed [7] - The board nominated candidates for the 6th Board of Directors, including both non-independent and independent directors, all requiring approval at the extraordinary general meeting [9][15][39] Group 3 - The company announced the date and details for the second extraordinary general meeting, scheduled for September 4, 2025, at 14:30 [21][20] - Voting will be conducted through a combination of on-site and online methods, with specific timeframes for each [22][24] - The company will provide reminders to minority investors to ensure their participation in the voting process [27]